GKB Ophthalmics Limited GKB NSEPHARMA
Company Overview
GKB Ophthalmics Limited engages in the manufacture and sale of unfinished ophthalmic lenses in India and internationally. It offers semifinished organic lenses, such as single vision, bifocal, and progressive. The company was incorporated in 1981 and is based in Mapusa, India.
Why Investors Should Care
Net profit has compounded at 276.0% per year over the last five years.
Revenue has grown at a 25.5% CAGR over the past five years.
Trades at a P/E of 26.4, below the sector median of 41.6.
Carries low leverage with a debt-to-equity ratio of 0.22.
Recent Developments
- Mar 2026 Revenue of ₹149.06 Cr (+36.8% YoY); net profit ₹1.22 Cr.
- Trailing 12 Months Year-on-year growth — revenue +36.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 25.5%, profit CAGR 276.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 25.52% |
| 1 Year: | 36.77% |
Compounded Profit Growth
| 5 Years: | 275.97% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -27.64% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)29.59 · Oversold
P/E of 26.43 is below the sector median of 41.64 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 25.5% over 5 years.
- Profit CAGR of 276.0% over 5 years.
CONS
- Trading 27.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GKB GKB Ophthalmics Limited NSEPHARMA | 63.97 | 26.43 | ₹32.24 Cr | 0.00% | 8.85% | 2.31% | 25.52% | 275.97% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 31.02 Cr | 32.31 Cr | 30.17 Cr | 56.79 Cr | 29.79 Cr |
| Cost of Revenue | 22.51 Cr | 21.89 Cr | 18.55 Cr | 45.35 Cr | 19.60 Cr |
| Gross Profit | 8.51 Cr | 10.41 Cr | 11.62 Cr | 11.44 Cr | 10.19 Cr |
| Operating Expenses | 12.16 Cr | 10.40 Cr | 9.39 Cr | 10.91 Cr | 7.88 Cr |
| Operating Income | -3.65 Cr | 71,000 | 2.23 Cr | 53.94 L | 2.31 Cr |
| EBITDA | -2.50 Cr | 1.00 Cr | 3.39 Cr | 2.23 Cr | 2.39 Cr |
| Interest Expense | 63.04 L | 76.63 L | 65.60 L | 73.45 L | 51.77 L |
| Pretax Income | -3.93 Cr | -56.34 L | 1.91 Cr | 67.72 L | 1.08 Cr |
| Tax Provision | 19.43 L | 7.73 L | 7.19 L | -3.00 L | -4.26 L |
| Net Income | -3.55 Cr | -1.02 Cr | 1.60 Cr | 44.30 L | 19.34 L |
| Diluted EPS | - | - | - | - | - |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 75.38 Cr | 88.25 Cr | 108.99 Cr | 149.06 Cr |
| Cost of Revenue | 51.29 Cr | 62.89 Cr | 76.56 Cr | 107.56 Cr |
| Gross Profit | 24.09 Cr | 25.37 Cr | 32.43 Cr | 41.51 Cr |
| Operating Expenses | 23.20 Cr | 27.68 Cr | 38.08 Cr | 36.11 Cr |
| Operating Income | 89.03 L | -2.31 Cr | -5.65 Cr | 5.40 Cr |
| EBITDA | 4.26 Cr | 1.51 Cr | -2.07 Cr | 8.17 Cr |
| Interest Expense | 1.30 Cr | 1.38 Cr | 1.57 Cr | 1.83 Cr |
| Pretax Income | 13.94 L | -2.78 Cr | -6.73 Cr | 3.10 Cr |
| Tax Provision | 2.31 L | 20.62 L | 35.30 L | 7.66 L |
| Net Income | -16.74 L | -2.81 Cr | -7.04 Cr | 1.22 Cr |
| Diluted EPS | - | - | - | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 112.09 Cr | 114.50 Cr | 125.21 Cr | 132.17 Cr |
| Current Assets | - | 83.53 Cr | 87.48 Cr | 99.39 Cr | 107.96 Cr |
| Cash & Equivalents | - | 2.36 Cr | 3.23 Cr | 3.02 Cr | 2.67 Cr |
| Inventory | - | 38.74 Cr | 40.02 Cr | 50.38 Cr | 54.63 Cr |
| Receivables | - | 27.74 Cr | 28.40 Cr | 25.49 Cr | 44.87 Cr |
| Total Liabilities | - | 44.79 Cr | 50.30 Cr | 68.78 Cr | 77.28 Cr |
| Current Liabilities | - | 41.09 Cr | 46.23 Cr | 62.39 Cr | 71.19 Cr |
| Long Term Debt | - | 1.17 Cr | 1.05 Cr | 3.08 Cr | 1.57 Cr |
| Total Debt | - | 11.22 Cr | 11.49 Cr | 14.50 Cr | 11.66 Cr |
| Total Equity | - | 62.69 Cr | 59.77 Cr | 52.04 Cr | 52.83 Cr |
| Shares Outstanding | - | 50.41 L | 50.41 L | 50.41 L | 50.41 L |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -2.77 Cr | 4.22 Cr | -3.43 Cr | -3.81 Cr |
| Investing Cash Flow | - | 1.43 Cr | -1.71 Cr | 2.55 Cr | 9.00 Cr |
| Financing Cash Flow | - | -2.19 Cr | -1.64 Cr | 66.88 L | -5.55 Cr |
| Capital Expenditure | - | -1.21 Cr | -2.08 Cr | -2.15 Cr | -1.03 Cr |
| Free Cash Flow | - | -3.99 Cr | 2.14 Cr | -5.58 Cr | -4.83 Cr |
| Net Change in Cash | - | -3.53 Cr | 86.83 L | -21.12 L | -35.43 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 32.0% | 28.7% | 29.8% | 27.8% |
| Operating Margin % | 1.2% | -2.6% | -5.2% | 3.6% |
| Net Margin % | -0.2% | -3.2% | -6.5% | 0.8% |
| ROE % | -0.3% | -4.7% | -13.5% | 2.3% |
| ROCE % | 1.3% | -3.4% | -9.0% | 8.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GKB
GKB Ophthalmics Ltd. Key Financial Ratios – Valuation, Profitability & More - Value Research
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQVTVWS2haMXZrT0hPdmZOb0x6dldtcEI5UHYwV2RIOU4yVUpyTVlmUWFwMXM3SDdPTWJ6d2M5MTZiVF9QS19OYVVGclcxam5wLWRrTFRraHVubGFPSnlUZmxvbG9EV2VWV2EwM050dEVwQ2w4NjFBQmNpdjE3cXlUTVpDNmJfZ2s?oc=5" …
GKB Ophthalmics shareholders unanimously approve all seven AGM resolutions - scanx.trade
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQYV9OemV5a3p3RzNpRDU1NW9xbmJ5UWswSHpwdFFGeUxpWkd2dFZhQ2J5UWJGOXRHbld3MG5lcFNDSnFHZmpxRWJjM2xtc0NKSVFEcHVfYWJLOXI4Y19ZZFpXcjV6OTMxcVV6VDJ3bU05MXpZcjlPNW9tZllkQkE2cWJ2U3M5WUltQVgyRG…
GKB Ophthalmics reports consolidated net profit of Rs 1.01 crore in the June 2026 quarter - Business Standard
<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxQcEdQTUNHZUVqVFYyWk1aNWdYUXowRUJRNm03aEtLMC0xOVhKdE9nWmc5RDRHVzdDeHFHRXZIREZXbWYxUEJYUTk1RlZhSmg3bF9HMlBVUTI4SjcwNlNnbEJkOVFiRUdONTQ4dGJLbTlqankwQWxYMXNFMzRCbGhyNXVhQ1FERjUwMnBfeE…
GKB Ophthalmics Ltd. Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOYXV3dVhnUHZYZ0tmc211ZVluc2J5cmhyN2NwOUJxRzJSVUpFTFNCREI0VEhvZlJzaXlrcEN4MDctWFlMd3lpS3FhVWJ1SERRdlhlb2tIM1dWaVEwTzFQdkxKOFFrM3VZVzJ5M3FDd0M3TEc3ZDd1UHpWMEFxdzRhMGZ1MEtiekpncHc?oc…
Latest rolling stock procurements: Via Rail, SNCF, GTLK, CAF, MAV, GKB, TMH - rollingstockworld.com
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQY2M2cDdFeHVhTGNoLTc0YzlMSEtlQy1GeGZLbUk3RDRyeHFjMHNGeTlobUlNc0FScnBDQnN3ZVFBelAxYTh3OTFkQWlQbzJSUnpmbFJ4YnlLTnFLYkpubzhLbkpidVY1b2NBUkdJQ0Rvd1B3RXYwd1lLaEk0OGdkNlQ1ZWxXU0FOUFhKcz…
UBS lands $2B team from Merrill Lynch - InvestmentNews
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPbmthM2lyRU9Wb2MtRDh4cmtmLVZhVE1VTk9VcmpHaHlwTWNINnJ0NnpaYk1oaXZRc0Y5MUR6YWRQQ0FmZ0NKV0oxWFB6YnYzdlJkenplZ1d4TDh4SDFhb1FDWDY0UjIyeDRRVmx5TW5JUzM3SDh1dmdMMnhHck5MOWpjY1VvS3B2Yjhhc3…
GKB — Frequently Asked Questions
What is the current share price of GKB Ophthalmics Limited (GKB)?
As of 2026-09-08 04:53 IST, GKB Ophthalmics Limited (GKB) trades at ₹63.97 on NSE. Its 52-week range is ₹60.90 to ₹88.40.
What is the market capitalisation of GKB?
GKB Ophthalmics Limited (GKB) has a market capitalisation of ₹32.24 Cr on NSE.
What is the P/E ratio of GKB?
GKB trades at a trailing price-to-earnings (P/E) ratio of 26.43. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 0.62.
What is the return on equity (ROE) of GKB?
GKB has a return on equity (ROE) of 2.31%. Its return on capital employed (ROCE) is 8.85%.
Is GKB a good stock to buy?
This page provides a data-driven analysis of GKB Ophthalmics Limited (GKB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.